ABBV-1088 for Healthy Subjects

Phase 1

Recruiting

Research Sponsored by AbbVie

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

History of cardiac disease, including congenital structural/conduction abnormalities, cardiomyopathy, myocardial infarction, cardiac arrhythmia

History of any clinically significant neurological, respiratory (except mild asthma as a child), endocrine, metabolic, renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to day 32

Summary

This trial will test the safety, tolerance, and how the body processes a single dose of ABBV-1088 in healthy adults.

Who is the study for?

This trial is for healthy adults who can safely participate in a study to test the effects of a new medication. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and not be taking conflicting medications.

What is being tested?

The trial is testing ABBV-1088, a new drug. Participants will receive either ABBV-1088 or a placebo (a substance with no therapeutic effect) to compare safety, tolerability, and how the body processes the drug.

What are the potential side effects?

Since this is an early-stage trial for ABBV-1088 in healthy individuals, potential side effects are being investigated; however, common side effects may include nausea, headache, dizziness or allergic reactions.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a history of heart disease or issues.

Select...

I do not have any major health issues apart from my cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to day 32

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to day 32

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 32 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-1088

Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-1088

Maximum Plasma Concentration (Cmax) of ABBV-1088

+4 more